Get the Stockscreener App
14.09
3.37%
0.46
After Hours:
14.10
0.010
+0.07%
Nextcure Inc stock is traded at $14.09, with a volume of 22,072.
It is up +3.37% in the last 24 hours and up +36.14% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$13.63
Open:
$13.67
24h Volume:
22,072
Relative Volume:
0.48
Market Cap:
$37.76M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-6.7416
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
+34.06%
1M Performance:
+36.14%
6M Performance:
+2,920%
1Y Performance:
+1,104%
1-Day Range:
$13.67
$14.35
1-Week Range:
$10.80
$15.74
52-Week Range:
$0.224
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
14.09 | 46.18M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure files for offering of up to 2.52 million shares of common stock by selling stockholdersSEC filing - MarketScreener
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
NextCure (Nasdaq: NXTC) in fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
NextCure Raises $21.5M in Private Placement - MSN
Will NextCure Inc. stock maintain momentum in 2025Trade Entry Summary & Reliable Trade Execution Plans - newser.com
Can NextCure Inc. stock sustain market leadershipQuarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com
How currency fluctuations impact NextCure Inc. stockEarnings Overview Report & Precise Buy Zone Tips - newser.com
How NextCure Inc. stock reacts to inflationary pressuresJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
FY2025 EPS Estimates for NextCure Boosted by HC Wainwright - Defense World
NextCure Inc. recovery potential after sell offMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Will NextCure Inc. stock gain from lower inflationProfit Target & AI Enhanced Trading Alerts - newser.com
Evaluating NextCure Inc. with trendline analysisEarnings Growth Report & Real-Time Volume Analysis - newser.com
Comparing NextCure Inc. in custom built stock radarsJuly 2025 Sector Moves & Low Volatility Stock Recommendations - newser.com
A activityJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - newser.com
NextCure secures $21.5 million in private placement to extend cash runway - Investing.com Canada
NextCure, Inc. Secures $21.5 Million in Private Placement, Extending Cash Runway into First Half of 2027 - Quiver Quantitative
NextCure (Nasdaq: NXTC) PIPE Extends Runway to 1H 2027 Ahead of 2026 ADC POC Data - Stock Titan
How to integrate NextCure Inc. into portfolio analysis toolsTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
How institutional ownership impacts NextCure Inc. stockBond Market & Verified Momentum Stock Watchlist - newser.com
Predicting NextCure Inc. trend using moving averagesRisk Management & Safe Entry Zone Identification - newser.com
Has NextCure Inc. found a price floorStock Surge & Long-Term Safe Investment Plans - newser.com
NextCure raises $21.5 million in private placement to fund ADC programs - Investing.com Canada
How sentiment analysis helps forecast NextCure Inc.Quarterly Performance Summary & Accurate Technical Buy Alerts - newser.com
NextCure Shares Jump 15% After Private Placement Announcement - Nasdaq
NextCure Raises $21.5M to Extend Runway and Advance ADC Programs - BioBuzz
NextCure raises $21.5 million in private placement to fund ADC programs By Investing.com - Investing.com South Africa
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules - The Manila Times
NextCure (NASDAQ: NXTC) announces $21.5M private placement to extend runway into 2027 - Stock Titan
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect? - Finviz
Why NextCure Inc. stock is favored by top institutions2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
NextCure, Inc. announced that it expects to receive $21.500024 million in funding - MarketScreener
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):